ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
PROK Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ProKidney Corp.NASDAQ: PROK
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $4.95M fell 22.9% year over year, ahead of the -38.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.3% from the prior quarter. Over 3 fiscal years it compounded at -30.2% a year.
Context
- Stock-based compensation amounted to 2837.2% of revenue in FY2025, down 35810.2 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -22.9% holds above the trailing-twelve-month pace of -38.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 25.34M USD
- Year-over-year change
- -13.7%
- 4-year CAGR
- +145.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.34M | -13.7% |
| FY2024 | 2024-12-31 | 29.37M | -4.8% |
| FY2023 | 2023-12-31 | 30.85M | -58.6% |
| FY2022 | 2022-12-31 | 74.47M | +10553.6% |
| FY2021 | 2021-12-31 | 699K | — |
Stock-Based Compensation vs competitors
How PROK compares with its peers on the latest reported figures
- PROK's LTM Mar 2026 stock-based compensation of $17.19M is the 4th largest of the 7 companies compared; the peer median is $11.53M.
- Its year-over-year change of -38.8% is the lowest of 6, against a peer median of +21.9%.
- Stock-based compensation amounts to 1933.5% of revenue for PROK, versus a peer median of 11.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $72.84M | +70.9% | +5.6% | 11.2% | |
| LTM Mar 2026 | $51.03M | +21.9% | +65.8% | 11.9% | |
| LTM Mar 2026 | $20.28M | +92.0% | +34.5% | 101.4% | |
| LTM Mar 2026 | $17.19M | -38.8% | -30.2% | 1933.5% | |
| LTM Mar 2026 | $2.79M | +13.0% | +36.8% | — | |
| LTM Mar 2026 | $2.1M | -12.1% | +36.1% | — | |
| LTM Dec 2024 | $0 | — | — | — | |
| Peer median (excluding PROK) | $11.53M | +21.9% | +36.1% | 11.9% | |
Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (55.15M) | (148.14M) | (135.45M) | (163.34M) | (151.61M) |
| Depreciation & Amortization | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 699K | 74.47M | 30.85M | 29.37M | 25.34M |
| Change in Working Capital | 2.16M | (6.46M) | 16.67M | 3.96M | 1.28M |
| Accounts Receivables | 0 | 0 | (1.38M) | (1.07M) | 1.32M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 5K | 494K | 11.64M | 11.59M | (5.92M) |
| Other Working Capital | 2.16M | (6.95M) | 6.41M | (6.56M) | 5.88M |
| Other Non-Cash Items | 0 | 0 | (6M) | (1.78M) | (1.7M) |
| Operating Cash Flow | (50.3M) | (77.09M) | (90.07M) | (126.35M) | (120.12M) |
| Capital Expenditures | (5.19M) | (1.85M) | (34.2M) | (29.51M) | (15.2M) |
| Acquisitions (Net) | 1K | 108K | 0 | 0 | 18.22M |
| Purchases of Investments | 0 | 0 | (471.6M) | (324.02M) | (217.08M) |
| Sales of Investments | 0 | 0 | 175.82M | 373.95M | 318.02M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.19M) | (1.74M) | (329.98M) | 20.41M | 103.97M |
| Debt Repayment | (30K) | (32K) | (52K) | (54K) | (26K) |
| Common Stock Issued | 71.5M | 6.05M | 0 | 144.32M | 25.6M |
| Common Stock Repurchased | 0 | 0 | (9.5M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 542.5M | 0 | 140K | 0 |
| Financing Cash Flow | 71.47M | 548.52M | (9.55M) | 144.41M | 25.57M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 15.98M | 469.69M | (429.6M) | 38.47M | 9.42M |
| Free Cash Flow | (55.49M) | (78.94M) | (124.27M) | (155.86M) | (135.31M) |
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.